January 3rd, 2022
ImmunoPrecise Antibodies Announces Grant of Stock Options
VICTORIA, British Columbia – January 3, 2022–IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board of directors has approved the...